Noroclav vet.

1 x 20 stk

Tablett

Innholdstoffer

Amoxicillin (Amoxicillin-trihydrat) : 40 mg

Klavulansyre (Kaliumklavulanat) : 10 mg

ATC-kode

QJ01CR02 amoksicillin og beta-laktamasehemmer

QJ01CR Komb. av penicilliner, inkludert beta-laktamasehemmere

QJ01C Beta-laktam antibakterielle midler, penicilliner

QJ01 Antibakterielle midler til systemisk bruk

QJ Antiinfektiva til systemisk bruk

Dyrearter

Dogs and cats.

Indikasjoner

For the treatment of the following infections caused by β-lactamase producing strains of bacteria sensitive to amoxicillin in combination with clavulanic acid:

• Skin infections (including superficial and deep pyodermas) caused by susceptible Staphylococci.

• Urinary tract infections caused by susceptible Staphylococci or Escherichia coli.

• Respiratory infections caused by susceptible Staphylococci.

• Enteritis caused by susceptible Escherichia coli.

It is recommended to carry out suitable tests for sensitivity testing when initiating the treatment. The treatment should only proceed if sensitivity is proven to the combination.

Dosering og tilførselvei

Oral use. The dosage rate is 12.5 mg combined actives/kg bodyweight twice daily. The tablets may be crushed and added to a little food.

The following table is intended as a guide to dispensing the product at the standard dose rate of 12.5 mg of combined actives per kg twice daily.

Bodyweight	Number of tablets twice daily
1-2	0.5
3-4	1
5-6	1.5
7-8	2
9-10	2.5
11-12	3
13-14	3.5
15-16	4
17-18	4.5

Duration of therapy

Acute cases: 5 to 7 days of treatment.

If no improvement is observed after 5 to 7 days, the diagnosis should be re-assessed.

Chronic or refractory cases: In these cases where there is considerable tissue damage, a longer course of therapy may be required so that it allows sufficient time for damaged tissue to repair. If no improvement is observed after two weeks, the diagnosis should be re-assessed.

Bivirkninger

Dogs and cats:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Gastrointestinal disorders (Diarrhoea, Vomiting)

Allergic reactions (e.g. skin reaction, anaphylaxis) ¹

Hypersensitivity reactions^¹

¹In these cases, treatment should be withdrawn.

² Unrelated to dose.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.